Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:11/8/2012

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor conferences:

  • Lazard Capital Markets 9th Annual Healthcare Conference
    Presentation: November 13, 2012, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at The Pierre Hotel in New York, New York
    Presenting: Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer 
  • Credit Suisse Healthcare Conference
    Presentation: November 14, 2012, at 3:00 p.m. Mountain Time (2:00 p.m. Pacific Time) at the Arizona Biltmore Hotel in Phoenix, Arizona
    Presenting: Craig M. Audet, Senior Vice President, Operations and Head of Global Regulatory Affairs
  • A live audio webcast of each presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of each presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

    About Arena PharmaceuticalsArena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, was approved by the US Food and Drug Administration in June 2012, and is under review for regulatory approval in additional jurisdictions. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.

    Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

    Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the regulatory review of BELVIQ; and Arena's focus, goals, strategy, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including the impact of competition; the timing and outcome of regulatory review is uncertain; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

    Media Contact: Russo PartnersCindy McGee, Vice President,

    David Schull, PresidentInvestor Relations & Alliance Management

    david.schull@russopartnersllc.comcmcgee@arenapharm.com  

    858.717.2310858.453.7200, ext. 1479 www.arenapharm.com
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
    2. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
    3. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    4. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
    5. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
    7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
    8. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
    9. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
    10. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
    11. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/23/2017)... 2017  A new genetic test has been ... individuals who carry HLA-B*15:02 and who ... potentially deadly side effect of certain medications used ... HLA-B*15:02 is strongly associated with life-threatening ... and toxic epidermal necrolysis in patients treated with ...
    (Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... devices market exhibits a consolidated vendor landscape with the ... the overall market in 2015. These companies are ... Industries, Inc., Hygia Health Services, Inc., and VANGUARD ... global reprocessed medical devices market is witnessing the ...
    (Date:3/23/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... it has acquired Agalimmune Ltd., a private UK-based company with ... $6 million upfront payment, of which $3 million is in ... may be made based on development and commercial milestones. ... Agalimmune,s lead ...
    Breaking Medicine Technology:
    (Date:3/23/2017)... ... 23, 2017 , ... The Wound Certification Prep Course ... Holdings, LLC, today announced that RestorixHealth® has officially endorsed WCPC as ... interested in becoming Certified Wound Specialist Physicians (CWSP®). , This collaborative effort ...
    (Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
    (Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
    (Date:3/23/2017)... ... March 23, 2017 , ... The ... facing life-altering and fatal diseases in opposition to the President’s Fiscal Year ... eviscerate care, services, and hope for the most vulnerable among us. , The ...
    (Date:3/23/2017)... Marina del Rey, CA (PRWEB) , ... March ... ... version of its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st ... iCode Assurance optimizes and accelerates the coding audit process for all medical chart ...
    Breaking Medicine News(10 mins):